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Abstract
Background: Herpes zoster (HZ) is a painful condition that can have a substantial negative impact on patients’ lives.
However, UK-specific data on the debilitating impact of HZ, in terms of patients’ experience of pain and impairments
in Health-Related Quality of Life (HRQoL) are limited. The Zoster Quality of Life (ZQOL) study, a large-scale UK
cross-sectional study, was conducted to quantify the burden of HZ in UK patients.
Methods: A total of 229 HZ patients aged 50 years or over were recruited from primary and secondary/tertiary care
centres throughout the UK. Patients completed a battery of validated questionnaires, including the Zoster Brief Pain
Inventory (ZBPI), the Medical Outcomes Study Short-Form 36 (SF-36) and the EuroQol-5 Dimensions (EQ-5D) on initial
presentation to the doctor and again 7–14 days later. At follow-up patients also completed the Treatment Satisfaction
with Medication (TSQM) questionnaire. Where available, mean questionnaire scores in the HZ population were
compared to scores for age-matched norms to investigate the burden associated with HZ.
Results: Pain was prominent among patients, with 57.9% at the initial study visit reporting pain in the preceding
24 hours at levels typically considered to have a significant impact on HRQoL (i.e. ZBPI worst pain ≥ 5). This was
reflected in SF-36 and EQ-5D scores that were significantly lower for patients when compared to age-matched norms
(p < 0.05) - except for the SF-36 domain of physical functioning. HRQoL was inversely associated with levels of reported
pain, with those patients in the greatest amount of pain reporting the greatest HRQoL impact. However, there was no
association between pain severity and participant age. The majority of patients (69.4%) received antivirals within
72 hours of rash appearing and 69.9% of patients were also taking analgesics for the management of HZ pain. TSQM
scores indicated that patients were least satisfied with the effectiveness of their prescribed treatment.
Conclusions: The acute presentation of HZ is a painful experience that can have a significant impact on the physical
and mental wellbeing of sufferers. Findings highlight significant unmet need among patients, particularly in terms of
the effectiveness of therapies for the management of HZ.
Background
Herpes Zoster (HZ), often referred to as ‘shingles’, is
a viral condition resulting from reactivation of latent
varicella-zoster virus (VZV) which is responsible for
childhood ‘chickenpox’ (primary infection). Approximately
one in four persons will develop HZ during their lifetime,
leading to an estimated 200,000 episodes in the UK annu-
ally [1]. Incidence of HZ increases with age, with the
majority of cases occurring in patients over 50 years of age
[2] and the risk of developing HZ being 50% or more in
those aged 80 years and over [3].
HZ manifests in three phases: prodromal, acute and
chronic (i.e. long-term complications that may result
from HZ). For many patients, each of the phases is char-
acterised by pain. Diagnosis and treatment occur in the
acute phase upon the presentation of a unilateral derma-
tomal rash, which may occur anywhere on the body but
most commonly presents on the trunk. The rash may
also be present around the nose and eyes (also known as
herpes zoster ophthalmicus (HZO)). The dermatological
rash and pain associated with HZ typically resolves
within one month of presentation [2]. However, despite
treatment, some patients may experience long-term com-
plications as a result of HZ. The most common and de-
bilitating complication of HZ is post-herpetic neuralgia
(PHN), commonly defined as pain persisting for 90 days
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or more following HZ rash onset and estimated to occur
in approximately 20% of sufferers [4].
Past cross-sectional, epidemiological studies have dem-
onstrated that the pain, and resulting discomfort, associ-
ated with HZ and PHN have a substantial and negative
impact on patients’ Health-related Quality of Life (HRQoL)
and patients’ ability to engage in activities of daily living
[5-11]. In addition to the burden encountered by the indi-
vidual with HZ, the condition is also associated with con-
siderable societal burden. Care provision for HZ and PHN
patients, in terms of visits to primary care (general practi-
tioner centres) and outpatient secondary/tertiary care cen-
tres (specialist pain clinics and ophthalmologists), inpatient
visits (hospitalisations) and prescription costs, for example,
is at considerable cost to healthcare systems [12-17]. Fur-
thermore, HZ and PHN are also associated with significant
indirect costs, primarily in terms of loss of productivity for
patients and caregivers [8,13].
To date, however, only limited real-world evaluation of
the burden of HZ and PHN specific to UK patients has
been conducted, and what research has been conducted
is limited by relatively small sample sizes and a lack of
geographic representation [8]. However, UK-specific data
are valuable to generate best available evidence for inform-
ing national healthcare decisions related to strategies for
the prevention and/or management of HZ and PHN.
There is a need, therefore, for the generation of more in-
formation to accurately ascertain disease burden in UK
patients; a view expressed by the UK Joint Committee on
Vaccination and Immunisation [18,19].
To address this need, the Zoster Quality of Life (ZQOL)
study, the first UK-wide real-world study designed to assess
the clinical characterisation, patient-reported burden and
wider societal burden associated with HZ and PHN was
conducted. HZ-specific information derived from the
ZQOL study is outlined herein (ZQOL study findings
for PHN patients are reported in a separate manu-
script) [20]. Specifically, the following information and
implications for such findings are considered: (1) dis-
ease presentation in UK HZ patients (2) burden of HZ for
UK patients aged 50 years and over in terms of subjective
experience of pain and HRQoL impact (3) economic
burden associated with HZ in terms of work loss prod-
uctivity and healthcare resource (e.g. prescribed medical
interventions, time spent with healthcare professionals




The ZQOL study adopted a cross-sectional observa-
tional design involving data collection from HZ/PHN
patients and their treating doctors (Figure 1). No medical
product or device was administered to study patients, nor
did participation in the study necessitate any change from
standard of care.
Recruitment
A total of 230 HZ patients were targeted for recruitment
to the ZQOL to ensure sufficient power for pre-specified
primary statistical analyses (i.e. comparison of patient-
reported outcome data collected from study collected
from study participants to published age-matched nor-
mative values for the respective instruments). This sample
size was verified via 100,000 Monte Carlo simulations,
using the Hochberg (1988) Step-up Procedure to control
for family-wise error rate in multiple comparisons [21]. As
a reflection of the typical management of HZ, ZQOL study
patients were recruited via incident case referrals from pri-
mary and secondary/tertiary care centres, throughout
England, Scotland, Wales and Northern Ireland [22].
Consecutive patients presenting with HZ at the site
as part of routine clinical practice were considered for
participation in the study. Patient eligibility for partici-
pation in the study was ascertained by doctor comple-
tion of a study-specific case report form. To be eligible
for participation in the ZQOL study patients were re-
quired to present to the doctor with a visible HZ rash
(i.e. unilateral crop of blisters and scabs in a dermato-
mal distribution). Furthermore, in accordance with data
suggesting that the incidence and severity of HZ in-
creases significantly in adults over the age of 50 [2], only
patients within this age range were eligible for participation
in this study.
To promote the ecological validity of the study (i.e. the
extent to which study setting, methods and materials ap-
proximate the real-world that is being examined), exten-
sive exclusion criteria were not employed. However, to
protect the integrity of study findings, HZ patients with
health impairments that may make it difficult for them
to complete the required battery of PRO instruments
(e.g. those with deficits in cognitive functioning or visual
impairments) were excluded from participation. Simi-
larly, patients whose medical background may make it
difficult to interpret study results (e.g. patients who have
taken part in a clinical trial related to HZ, pain and/or
immunomodulating therapy in the past 6 months or
patients who were previously experiencing neuropathic
pain in the dermatomal region of their HZ rash prior to
the onset of HZ due to another aetiology) were also ex-
cluded. Of note, PRO instruments were only provided in
English and non-English speakers were excluded from
participation in the study.
Study procedures
Prior to recruitment of study patients, all site staff re-
ceived formal training in study procedures, including
procedures for administering Patient-Reported Outcome
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(PRO) questionnaires to patients to ensure standardisa-
tion and minimisation of missing data (e.g. ensuring that
patients do not receive additional help from anyone when
completing the questionnaires and that questionnaires are
thoroughly checked for completeness). In addition, as a
pre-requisite of site participation, all site staff were re-
quired to demonstrate evidence of completion of good
clinical practice training.
At the initial site visit, once informed consent had
been obtained and participant eligibility for partici-
pation confirmed, patients were asked by study staff
to complete a combination of validated and specially de-
signed PRO questionnaires. All questionnaires were bound
in a study booklet to ensure standardisation of presenta-
tion and order of completion among all patients. Partici-
pants were informed prior to obtaining consent that
completion of the PRO questionnaires should take no
more than 30 minutes.
There is no consensus in the research literature as to
the stage of the acute HZ episode at which pain and
HRQoL impact are at their highest [6,23]. Therefore, to
ensure that the patient-reported impact of acute HZ was
not underestimated by data collection on initial presen-
tation, all patients were provided with additional copies
of the validated PRO questionnaires which they were
asked to complete at home and return 7–14 days after
their original visit.
Study questionnaires
Data were collected using the following PRO questionnaires:
 Patient socio-demographic questionnaire: Used
to collect patient socio-demographic data (age,
gender, ethnicity, living situation, education level
and employment status) and data concerning patients’
experiences of HZ (e.g. symptoms during the acute
phase of disease presentation). In addition this
questionnaire also included questions concerning
the impact of shingles on patients’ daily lives (e.g.
impact on work productivity, number of days unable
to work/take part in daily activities such as housework
and hobbies). Details of medical care (e.g. number of
doctor consultations) and treatment (e.g. use of
non-prescription drugs) for shingles were also
collected. Completed at initial visit only.
 Zoster Brief Pain Inventory (ZBPI) [24]: The
ZBPI is designed specifically to evaluate pain
intensity due to HZ (which may include allodynia
and pruritus) and the extent that this may
interfere with respondent’s activities of daily
living. The instrument comprises 15 items taken
from the Brief Pain Inventory-Short Form, a
well-validated PRO measure applied in a broad
spectrum of medical conditions [25] and includes
four items assessing ‘Pain severity’ and seven
Figure 1 Overview of study methodology.
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items assessing ‘Pain interference’. All items comprising
these subscales are assessed via 11-point numerical
rating scales ranging from 0 (no pain/does not
interfere) to 10 (pain as bad as you can imagine/
completely interferes). Prior research has shown
the ZBPI to be a reliable and valid assessment of
pain severity and impact for use in HZ patients
[24] and the instrument has been utilised in prior
cross-sectional investigations [5,6,8]. Completed at
initial visit and follow-up.
 MOS 36-item Short-Form Health Survey (SF-36)
Acute Form [26]: The SF-36 is a standardised
generic questionnaire that consists of 36 items
evaluating HRQoL. The psychometric validity of the
SF-36 is well-established. In particular, the SF-36 has
demonstrated validity for use in HZ and PHN
populations [10,11]. Items explore the following eight
dimensions: physical functioning, role functioning
due to physical problems, role functioning due to
emotional problems, bodily pain, general health
perceptions, vitality, social function and mental health.
Two summary scores, the Physical Component
Summary (PCS) and Mental Component Summary
(MCS), can also be calculated. The acute form differs
from the standard form of the SF-36 in that it employs
a recall period of ‘during the past week’ (rather than
‘during past 4 weeks’) which is more appropriate for
short-term conditions such as HZ. Scores for the eight
scale dimensions and two summary scores were
calculated using norm-based scoring (NBS) algorithms
which employ a linear T-score transformation with
mean = 50 and standard deviation = 10 – making it
possible to meaningfully compare scores across
domains/summary scores [27]. Completed at initial
visit and follow-up.
 The EuroQoL 5 Dimensions questionnaire
(EQ-5D) [28]: The EQ-5D is a standardised generic
questionnaire comprising 5 items that are used
to provide a simple descriptive profile and a single
index value for health status (ranging from 0-1):
EQ-5D Health State Index (HSI). In addition, the
EQ-5D also includes a patient-completed visual
analogue scale, which records the respondent’s
self-rated health (SRH) on a vertical scale where the
endpoints are labelled from 0 (‘worst imaginable
health state’) to 100 (‘best imaginable health state’).
Completed at initial visit and follow-up.
 Treatment Satisfaction Questionnaire for
Medication (TSQM) Version II [29]: The TSQM
Version II is an 11-item questionnaire designed to
assess patients’ satisfaction with various aspects of
their medication, including side effects (3 items + 1
yes/no stem), effectiveness (2 items), convenience
(3 items) and overall treatment satisfaction (2 items).
Items are assessed using 5-point and 7-point
Likert scales ranging from ‘Extremely dissatisfied’
to ‘Extremely satisfied’, but scores on all domains are
transformed to a 0-100 scale whereby higher scores
indicate greater levels of patient satisfaction.
Completed at follow-up only.
To complement and facilitate interpretation of PRO
data, data concerning patient’s clinical and treatment
history were collected as part of the doctor-completed
case report form.
Ethics
The ZQOL study was designed and conducted in ac-
cordance with the principles set forth in the Declaration
of Helsinki [30]. In accordance with current research
governance frameworks in the UK, ethical approval of
the study was obtained from the National Research Ethics
Service before data collection began. Furthermore, as the
study involved use of National Health Service (NHS) staff,
premises, resources and data, local R&D management
approval was obtained from the respective NHS local au-
thorities before research began at each site [31]. Finally,
informed consent was obtained from patients prior to the
collection of data from themselves or their doctor and
all data were handled in accordance with the 1998 Data
Protection Act.
Statistical analyses
All planned statistical analyses were specified a priori in
a formally developed Statistical Analysis Plan (SAP). All
study data were subject to extensive quality control
checks prior to the conduct of analyses. Where doctor-
reported information was not clear, follow-ups with doc-
tors were made to resolve queries. In accordance with
developer instructions, if missing data for a SF-36 domain
were < 50% then data were imputed using the mean of par-
ticipants’ responses to the completed items [26]. Missing
data for the ZBPI, SF-36 (where >50%), EQ-5D and TSQM
were not imputed and where item scores were missing,
relevant domain scores were not calculated.
To quantify the burden associated with HZ, mean SF-
36 and EQ-5D scores from ZQOL study samples were
compared to published age-matched normative values
for the respective questionnaires [32,33]. The statistical
significance of differences was investigated via the con-
duct of unifactorial tests. Differences of equal to or
greater than 0.5 standard deviation units of a baseline
or comparator score were characterized as clinically mean-
ingful [34-36].
In addition, a number of sub-analyses were conducted
upon patient scores on the composite domains of the
ZBPI (pain severity and pain interference), SF-36 (PCS
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and MCS) and EQ-5D (HSI and SRH) to test a number
of pre-specified hypotheses, including:
Age: Prior research has indicated HZ disease sever-
ity increases with age [37]. The association between
patient age and reported pain severity, pain interfer-
ence and HRQoL impact was investigated via calculation
of Spearman Rho correlation coefficients.
Gender: In light of previous evidence suggesting differ-
ential reports of pain severity, pain interference and
HRQoL impact by gender across a range of medical con-
ditions (including HZ) [38,39], mean composite scores
among male and female patients were compared using
unifactorial tests.
Antiviral use: There is evidence to suggest that use of
antivirals within 72 hours of rash onset can reduce the
severity and duration of the HZ episode [40-42]. To ac-
count for any potential differential impact, therefore,
follow-up data for patients prescribed an antiviral within
72 hours of rash onset were compared to those who re-
ceived an antiviral more than 72 hours after rash onset.
Pain severity (ZBPI ‘Worst pain’): It was expected that
pain interference and HRQoL impact would be greatest
among patients reporting the greatest levels of pain. Pain
interference and HRQoL were therefore to be compared
amongst groups of patients stratified according to empiric-
ally confirmed categorisations of scores on the ‘Worst pain’
item of the ZBPI: none (0); mild (1–4); moderate (5–6);
severe (7–10) [43]. ZBPI ratings of ‘Worst pain’ were con-
sidered as past research has indicated that ratings of ‘worst
pain’ are the more reliable than ratings of ‘average’ or
‘current’ pain [24].
In order to explore potential predictors of pain and
HRQOL (as assessed by composite scores for the afore-
mentioned PRO questionnaires), a series of ordinary least
squares (OLS) regression analyses were conducted. Inde-
pendent predictor variables included: socio-demographic
variables (age, gender, ethnicity, BMI etc.); time elapsed
since first appearance of rash; diagnosis of HZO; antiviral
prescription within 72 hrs of rash presentation; level of an-
algesics used (level 1 vs. level 2 vs. level 3); hospitalisations




A total of 229 HZ patients (214 HZ, 15 HZO) were re-
cruited to the ZQOL study between April 2010 and May
2011 (Table 1). Both age [5,12] and gender distributions
[5,6,10-12] of the study sample are consistent with prior
epidemiological investigations of the incidence of HZ in
the UK and previous studies in the US, Canada and
Europe. Of further note, reports from study sites suggest
that very few patients approached were deemed ineligible
for participation in the study.
Table 1 HZ ZQOL study patients: socio-demographic data
Characteristic HZ patients (n = 229)




Not stated 2 (0.9%)
Body Mass Index (BMI) – mean (Range) 27.7 (19 – 49)
Ethnicity n (%)
White/Caucasian 225 (98.3%)
Mixed race 1 (0.4%)
Not stated 3 (1.3%)
Comorbidities n (%)








Highest level of education n (%)
Secondary school or less 88 (38.4%)
O level or equivalent 48 (21.0%)
A level or equivalent 16 (7.0%)
Vocational 44 (19.2%)
Undergraduate degree 15 (6.6%)
Post graduate degree 13 (5.7%)
Not stated 5 (2.2%)
Work status n (%)
Full or part time employment 66 (28.8%)
Retired 146 (63.8%)
Unable to work for medical reasons 9 (3.9%)
Unemployed 3 (1.3%)
Mature student 1 (0.4%)
Other 2 (0.9%)
Not stated 2 (0.9%)
Living situation n (%)
Living alone 45 (19.7%)
Living with partner 148 (64.6%)
Living with partner and children 20 (8.7%)
Living with children 7 (3.1%)
Living in communal residence (e.g. care home) 2 (0.9%)
Other 5 (2.2%)
Not stated 2 (0.9%)
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Characterisation of HZ episode
For 79.9% (n = 183) of HZ patients, this was their first
episode of the disease. Among patients who had experi-
enced HZ before, the majority had experienced just one
prior episode. That 20.1% (n = 46) of patients were
experiencing a recurrent episode of HZ (albeit based
on patients’ own reports and not confirmed clinical
diagnoses) suggests that HZ is not a once in a life-
time event and supports recent evidence indicating that re-
current episodes of HZ are more common than previously
reported [44].
Almost all patients (97.4%; 223) were described by
their physicians as presenting with classic HZ (i.e. a uni-
lateral crop of blisters in a dermatomal distribution).
The majority of HZ rashes were described by doctors as
being erythematous (72.1%; n = 165) or simple vesicles
(62.9%; n = 144) in appearance, of a small size (48.5%;
n = 111) and a medium density (54.1%; n = 124). Among
ZQOL study patients, the HZ rash most commonly af-
fected more than one site of the body (60.3%; n = 138)
and most frequently presented on the chest/rib cage
(59.0%; n = 135), abdomen/flanks (41.0%; n = 94), and
head and neck (30.1%; n = 69) (Figure 2). Of note, despite
concerted efforts to recruit such patients to the study via
ophthalmologists, the proportion of patients with HZO
patients recruited to the ZQOL study (6.6%; n = 15) was
less than projected population estimates (10-20%) [22].
The vast majority (90.4%; n = 207) of HZ patients re-
ported experiencing pain due to their HZ rash. Reports
from patients indicated that this pain was persistent in
nature, being present ‘Most of the time’ (44.1%; n = 101)
or ‘All the time’ (15.3%; n = 35). The experience of pain
following HZ rash onset was qualitatively similar to that
experienced prior to rash onset with ‘tender’ (52.0%;
n = 119), ‘sensitive’ (40.6%; n = 93), ‘itching’ (38.4%; n = 88),
‘burning’ (35.8%; n = 82) and ‘aching’ (33.6%; n = 77) emer-
ging as the terms most frequently selected by patients to
describe their pain.
In addition to pain, findings from the ZQOL study re-
veal that HZ patients also experience a range of other
symptoms during the acute phase of HZ. In particular,
symptoms of fatigue (70.7%; n = 163), stomach upsets
(30.6%; n = 70), change in bowel movements (27.1%;
n = 63) and muscle weakness (27.1%; n = 63) were com-
monly experienced by study patients. This is in contrast to
prior research which suggests that such symptoms occur
in <20% of patients [23].
Quantification of pain experienced by HZ patients: ZBPI
ZBPI scores from ZQOL study patients indicated that
pain severity and pain interference, as assessed by ZBPI
composite scores and individual ZBPI items, were high-
est on initial presentation to the recruiting doctor with a
visible HZ rash than compared to 7–14 days later at
follow-up (Figure 3). During this initial visit more than
half of all HZ patients (57.6%; n = 132) gave ratings of
‘Worst pain’ experienced in the past 24 hours that are
indicative of significant HRQoL burden (i.e. worst pain
score ≥ 5).
Comparison of patient ratings of pain as defined ac-
cording to empirically established cut-offs for the ZBPI
worst pain item (1–4 =mild pain; 5–6 =moderate pain;
7–10 = severe pain) [45] and doctor ratings of pain
(mild, moderate and severe) indicated agreement in only
40.6% of cases. Where disagreement occurred, doctors
were more likely to underestimate (35.6%) than overesti-
mate (23.7%) patients’ experience of pain. These findings
are consistent with previous research that has indicated











Head & neck (30.1%)
Figure 2 Area of body affected by HZ among ZQOL study patients (n = 229).
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a disparity between patient and doctor and assessments
of pain [46].
In contrast to prior research suggesting a link between
HZ pain severity/interference and age [37], calculation
of Spearman rho correlation coefficients revealed no sig-
nificant association between patients’ age and composite
pain severity and pain interference scores (Table 2).
Investigation of ZBPI pain scores revealed that females
scored significantly higher than males in terms of pain
severity. Differences for pain interference, however, were
non-significant (Table 2). Further subgroup analyses re-
vealed pain severity and interference to be highest among
patients prescribed antivirals within 72 hours of rash,
compared to those not prescribed antivirals within this
Figure 3 ZBPI domain and component scores among HZ ZQOL study patients at initial visit and follow-up. No *s p≥0.05, *p<0.05.
Table 2 HZ pain severity/interference (ZBPI) and HRQOL impact (SF-36 & EQ-5D) at initial visit: ZQOL study subgroup
analyses






















Pain Severity −0.0720 NS 3.4 4.0 * 3.9 3.4 NS N/A N/A N/A N/A N/A





−0.0903 NS 40.9 42.1 NS 43.2 46.2 NS 48.3 44.8 41.0 36.07 ***
SF-36 Mental Component
Summary (MCS)





−0.0295 NS 66.7 59.6 ** 63.8 73.1 NS 70.0 70.1 59.7 54.6 ***
EQ-5D Health State Index
(HSI)
−0.0635 NS 0.68 0.61 NS 0.63 0.70 NS 0.81 0.70 0.66 0.52 ***
NS p ≥ 0.05, *p < 0.05; **p < 0.01; ***p <0.001. † = clinically meaningful difference.
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timeframe (although only differences for pain interfer-
ence were statistically significant). This may reflect that
patients with high levels of pain are more likely to con-
sult with their doctor early and be prescribed antivirals
within 72 hours or rash onset. As expected, a significant
linear relationship was also observed in mean pain inter-
ference scores for patients classified according to empir-
ically confirmed cut-offs for pain severity (Table 2).
Prediction of ZBPI composite scores via ordinary least
squares regression analyses revealed that patient use of
level 2/3 analgesics (r2 = 0.065), patient BMI (r2 = 0.043),
the length of time since the patient’s HZ rash first ap-
peared (r2 = 0.030) and presence of a respiratory disorder
(r2 = 0.023) were able to explain 14.2% of the variance in
ZBPI pain severity composite scores. Similar regression
analyses revealed that patient ratings of ‘worst pain’
(r2 = 0.268), use of level 2/3 analgesics (r2 = 0.024) and
presence of a respiratory disorder (r2 = 0.016) accounted
for 36.0% of the variation in pain interference scores.
HZ impact on HRQoL: SF-36
HZ patients demonstrated significant deficits on all SF-36
domain and summary scores at both initial and follow-up
visits (except for Physical functioning) compared to values
derived from an age-matched normative population
(Figure 4). Deficits, compared to norm values, were gen-
erally greatest for SF-36 domains assessing mental func-
tioning, with clinically meaningful deficits observed for
domains of ‘Vitality’, ‘Social-functioning’, ‘Role-emotional’
(follow-up only), ‘Mental health’ and the MCS.
Calculation of spearman rho correlation coefficients
revealed no significant association between patients’ age
and PCS and MCS scores. Significant differences were
also not observed between subgroups of HZ patients de-
fined according to antiviral use. Differences in PCS and
MCS scores were observed between male and female
HZ patients, with females scoring lower on both do-
mains. However, differences were only statistically sig-
nificant for MCS scores. A significant linear relationship
between PCS and MCS scores was observed for patients
classified according to empirically confirmed cut-offs for
pain severity (Table 2).
Ordinary least squares regression analyses revealed the
presence of rheumatoid/neurological disorders (r2 = 0.061),
patient ratings of ‘worst pain’ (r2 = 0.048), use of level 2/3
analgesics (r2 = 0.043), patient BMI scores (r2 = 0.035) and
the presence of a respiratory disorder (r2 = 0.021) collect-
ively explained 27.2% of the variance in PCS scores. Similar
regression analyses revealed that patient ratings of ‘worst
pain’ (r2 = 0.039), patient’s gender (r2 = 0.033), prescription
of antiviral medication within 72 hours of the onset of the
HZ rash (r2 = 0.029) and presence of a psychological/
psychiatric disorder (r2 = 0.023) accounted for 12.1% of the
variance in MCS scores.
HZ impact on HRQoL: EQ-5D
Consideration of individual EQ-5D scores indicated that
‘Pain’ was the most prevalent problem reported by pa-
tients (>80%) at both the initial visit and at follow-up
(Figure 5). Mean scores on the Self-rated health (SRH)
and Health state index (HSI) were marginally lower at
the initial visit when compared to the follow-up visit
(differences non-significant). At both visits, however, SRH
and HSI scores were significantly lower than the age-
matched norms (Table 3).
Calculation of spearman rho correlation coefficients
revealed no significant association between patients’ age
and SRH and HSI scores. Significant differences were
also not observed between subgroups of HZ patients de-
fined according to antiviral use. Differences in SRH and
HSI scores were observed between male and female HZ
patients, with females scoring lower on both domains.
Differences, however, were only statistically significant
for SRH scores. A significant linear relationship between
SRH and HSI scores was observed for patients classified
according to empirically confirmed cut-offs for pain se-
verity (Table 2).
Ordinary least squares regression analyses indicated that
the presence of rheumatoid/neurological (r2 = 0.049), psy-
chological/psychiatric (r2 = 0.034), or ‘uncategorised’ disor-
ders (r2 = 0.016), the ‘Worst pain’ experienced (r2 = 0.085)
and patient use of level 2/3 analgesics (r2 = 0.021) ex-
plained 22.0% of the variance in SRH scores. The presence
of a psychological/psychiatric (r2 = 0.025), rheumatoid/
neurological (r2 = 0.043), the ‘Worst pain’ experienced
(r2 = 0.041) and patient use of level 2/3 analgesics
(r2 = 0.073) explained 20.7% of the variance in HSI scores.
Productivity losses in HZ patients
Of the 63/229 HZ patients that were working, 39
(61.9%) reported that their work had been affected by
their HZ with 32 of these patients having to take time
off work as a result of their HZ. Among those patients
who reported that their work had been affected by their
HZ, the average number of days off work was 5.4 days
(range = 0–28). Reports from the entire HZ patient sam-
ple indicate that the mean number of days that they
were unable to take part in their usual activities was
3.9 days (range = 0–21).
Impact of HZ on medical resource use
Clinician reports indicated that HZ patients were taking
an average of four medications to treat their HZ (3.89,
SD = 1.01). Antiviral therapies (predominately acyclovir)
were the most common treatment prescribed by doctors
for the management of HZ (88.2%; n = 202) with the ma-
jority of patients (69.4%; n = 159) prescribed antivirals
within 72 hours of the onset of their rash, the time-
frame in which they have demonstrated efficacy [40-42].
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Figure 5 Per cent of HZ patients reporting any problem on EQ-5D domains at initial visit and follow-up.
Figure 4 SF-36 domain and component scores among HZ ZQOL study patients at initial visit and follow-up. No *s p≥0.05, *p<0.05;
**p<0.01; ***p <0.001. † = clinically meaningful difference. PF=Physical functioning, R-P=Role-physical, BP=Bodily pain, GH=General health,
V=Vitality, SF=Social functioning, R-E=Role-emotional, MH=Mental health, PCS=Physical component summary, MCS=Mental component summary.
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Prescription analgesics (including Level 1, Level 2, Level 3,
local anaesthetic/analgesics and topical analgesics) and
non-prescribed analgesics (including paracetemol and ibu-
profen) were also widely used by patients (71.2% and 41.9%
respectively). For the majority of patients this was the first
time that they had seen a healthcare professional in rela-
tion to their HZ (87.3%; n = 200). Follow-up visits were
only anticipated for 25.8% (n = 59) of patients. Planned re-
ferrals to other healthcare professionals (3.5%; n = 8) and
additional investigations (4.4%; n = 10) were low and only
one patient reported being hospitalised due to their HZ
(due to central nervous system complications).
Treatment satisfaction among HZ patients (TSQM)
HZ patients were classified according to antiviral and
analgesic medication use. Across all groups, TSQM
scores indicated that patients were least satisfied with the
perceived effectiveness of treatment and most satisfied
with the side effects experienced. No significant or clinic-
ally meaningful differences were observed between pa-
tients receiving different treatment for the management
of their HZ (Figure 6).
Discussion
The value of real-world data summarising patients’ expe-
riences of living with a health condition in informing de-
cisions regarding the management of that condition and
access to new medicines in national markets are becom-
ing increasingly recognised. As stipulated in the UK
Government’s Health and Social Care Act, the proposed
commissioning outcomes framework (which is a funda-
mental foundation of the proposed NHS reforms in
England) will place a strong emphasis on promoting
decision-making that is driven by the patient experi-
ence; as likely measured by PRO questionnaires [47].
Conducted against the backdrop of a challenging en-
vironment for UK observational research [48], the ZQOL
study is the first UK-wide study designed to investigate the
burden and unmet needs among HZ patients in the UK.
Understanding the experience of pain and HRQOL burden
in UK HZ patients
Results from the ZQOL study indicated that more than
half of study participants with HZ (57.9%) reported pain
at levels typically considered indicative of significant
HRQOL burden [24]. There is limited consensus on the
stage at which pain during an acute HZ episode is at its
highest [6,23]. However, findings from the ZQOL study
indicated that pain was greater on initial presentation to
the doctor than compared to follow-up 7–14 days later.
That the pain associated with HZ may result in signifi-
cant HRQoL impairments among HZ patients is well-
documented [5-11]. Only rarely in literature published
to date, however, has the degree of burden experienced
by HZ patients been interpreted with reference to HRQoL
readings among normative populations [11]. Comparison
of scores on standard generic measures of HRQoL (SF-36
and EQ-5D) to those elicited from age matched normative
populations revealed significant deficits across all facets
of HRQOL among HZ patients. Deficits among partici-
pants were most notable among the mental/affective
components of HRQoL and participants ability to perform
Figure 6 TSQM domain scores among HZ study patients, categorized according to prescribed treatment. Note that due to small sample
sizes, results for patients receiving no antiviral in combination with level 1 analgesics (n=6) or level 2 analgesics (n=5) have not been presented.
Table 3 Comparison of EQ-5D SRH and HSI scores at initial
visit and follow-up to age-matched population norms
Outcome variable (n) Norm Initial (p) Follow-up (p)
EQ-5D SRH: Self-Rated Health (229) 77.3 62.4***† 66.6***†
EQ-5D HSI: Health State Index (227) 0.78 0.65***† 0.66***
***p <0.001. † = clinically meaningful difference.
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usual activities where statistically significant and clinically
meaningful deficits were observed.
Consistent findings across the PRO measures employed
in the ZQOL study were observed. For example, that a
high proportion of patients experienced problems con-
ducting usual activities (as measured by the EQ-5D) is
consistent with significant and clinically meaningful defi-
cits observed for SF-36 domains of Role-Physical and So-
cial Functioning and ZBPI ratings of interference on
general activities. Similarly, reports of high levels of inter-
ference in sleep (as measured by the ZBPI) are consistent
with statistically and clinically meaningful deficits ob-
served for the SF-36 Vitality domain. Furthermore, that
problems with Self-Care were least frequently reported by
participants completing the EQ-5D is also consistent with
SF-36 scores for Physical Functioning where statistically
significant deficits compared to norms were not observed.
Statistically and clinically meaningful deficits observed for
the SF-36 domains of Role-Emotional and Mental Health,
however, indicate that the mental impact of HZ is likely to
extend beyond anxiety and mood (as measured by the
EQ-5D and ZBPI, respectively).
Investigation of the burden of HZ in this manner is
important for understanding the value of therapies in a
given disease area and for facilitating decisions regarding
reimbursement. This is particularly true for countries
(including the UK), where health authorities may have to
determine allocation of finite resources across different
diseases. The introduction of Value-Based Pricing (VBP)
of medicines into the NHS in 2014, for example, will
mean increased emphasis being placed on the generation
of robust real-world evidence to support pricing and re-
imbursement decisions [49].
Limitations on available resources often mean that
there is pressure on health providers to target resources
to those patients with the greatest health needs. Consist-
ent with hypotheses of a linear relationship between pain
severity, pain interference and HRQoL impact, patient-
reported levels of pain severity were found to the most
consistent and most significant predictor of HRQoL bur-
den. Specifically, the greatest levels of burden were ob-
served in those patients experiencing the most severe
levels of pain [6,7,9,10]. However, whilst the prevalence
of HZ may be associated with age, findings from the
ZQOL study indicate that pain severity and subsequent
HRQOL are not predicted by age. Consistent with prior
research, however, findings did suggest that pain severity
and associated deficits in HRQoL were greatest among
female patients. Differences between males and females,
however, were not significant in all cases [38,39].
Economic burden of HZ
Prior research findings from retrospective reviews of
medical records and databases indicate that care of HZ
patients is associated with significant direct and indirect
costs [12,14-16,50]. Direct costs associated with treat-
ment of HZ (including medication costs, doctor visits
and hospital admissions) equate to approximately £198
per episode [51]. This seemingly low cost is likely a re-
flection of the acute presentation of the disease. This is
supported by data from the ZQOL study which suggests
that, during this time period, resource use among HZ
patients is relatively low. For example, beyond the initial
consultation, the majority of HZ patients in the ZQOL
study (73.4%) were unlikely to be seen again by their
doctor in relation to their HZ. Furthermore, rates of
referrals to healthcare professionals, additional investi-
gations and hospitalisations as a result of HZ (during
initial presentation) were all very low (Note that the
long-term implications of HZ are documented in the
PHN ZQOL sub-study) [20]. Findings from the ZQOL
study, however, indicate that significant losses in prod-
uctivity may be associated with HZ. This is particularly
true among those sufferers not yet at retirement age. For
example, two thirds (39/63) of ZQOL patient with HZ
and currently in full or part-time employment noted that
their work had been affected by their condition, predom-
inately in terms of time taken off work. Previously pub-
lished research has indicated that, when productivity
losses are taken into account, the cost per episode of HZ
can be as much as £526 [8].
Treatment evaluation
Existing guidelines for healthcare professionals recommend
that all HZ patients ≥50 years be prescribed antivirals
for the management of their condition [52]. Consistent
with recommendations, antivirals were the most com-
mon treatment prescribed to ZQOL study participants,
followed by World Health Organization (WHO) level
1/2/3 and topical analgesics. Whilst the efficacy of anti-
viral and analgesic medications has been confirmed in
the context of clinical trials, there have been only lim-
ited attempts to conduct real-world evaluations of these
products from the patients’ perspective. Patients’ satis-
faction with treatment is an important indicator of
treatment outcomes, not least because it is a significant
predictor of patients’ adherence to treatment regimens.
To date, however, there has been no attempt to quan-
tify patient satisfaction with HZ medications using stan-
dardised assessments of treatment satisfaction. Consistent
with assertions that antiviral and analgesic medications
are generally well-tolerated, analysis of TSQM scores sug-
gested that patients were most satisfied with the side-
effects of their treatment. Regardless of the treatment
received, lowest levels of satisfaction were reported in re-
lation to the efficacy of the prescribed treatment. This is
perhaps not surprising given that the majority of patients
were experiencing pain – to a clinically significant degree
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in a substantial proportion of patients – despite receiving
treatment for their HZ.
Implications of ZQOL study findings for management of
HZ in the UK
Findings from the ZQOL study have implications in
terms of provision of frontline services for HZ and pa-
tients and wider implications in terms of the national
availability of means to prevent and manage HZ.
As life expectancy throughout the developed world
continues to rise, effective management of HZ becomes
increasingly important in order to minimise the individ-
ual patient and societal burden associated with these
conditions. Findings from the ZQOL study support the
notion that, in order to address the unmet needs preva-
lent among HZ patients and to reduce the economic
burden associated with HZ, there is a need to move
away from therapies designed to manage the symptoms
of HZ. Rather, more targeted therapies designed to re-
duce the burden of HZ by preventing VZV reactivation
and attenuating pain severity during the HZ rash and
persistence of pain following the resolution of the HZ
rash are needed. This is in line with worldwide health
authority initiatives, which have stressed the prioritisa-
tion of preventative measures, so as to reduce the bur-
den on healthcare conditions on individuals, healthcare
systems and society as a whole [53]. Furthermore, this is
also in line with the Quality, Innovation, Productivity
and Prevention (QIPP) initiative recently introduced by
the UK Government [54].
Recent years, have seen documented evidence of the
efficacy of a VZV vaccine in the prevention of HZ and
PHN episodes and attenuation of the severity of HZ and
PHN episodes and associated impact [55]. The VZV vac-
cine, Zostavax® (shingles (herpes zoster) vaccine (live))
was originally approved by the US Food and Drug Ad-
ministration and European Medicines Agency for use in
patients aged 60 years and above and more recently has
gained approval for use in patients aged 50 years or
above. That no link was observed between a patient’s
age and HZ pain severity and associated impact in the
ZQOL highlights the potential value of vaccination in
some patients < 60, particularly as it is among these pa-
tients where productivity losses may be most apparent.
From the perspective of frontline service provision,
findings from the ZQOL study indicate the need for bet-
ter observation and monitoring of patients treated in
primary care to ensure adequate management of HZ.
The disconnect evident between patient and doctor as-
sessments of disease severity, especially in terms of se-
verity of pain experienced, indicates the need for doctors
to ensure open communication with patients in terms of
their current experiences of HZ and PHN. In addition,
there appears to be dissatisfaction among HZ patients,
especially with regard to the perceived efficacy of treat-
ments, which is presumably driven by experience of in-
adequate relief of symptoms. Thus, doctor communication
of the value of prescribed therapies and setting realistic pa-
tient expectations of treatment outcomes may also help to
improve adjustment in patients with HZ. Use of standar-
dised PRO questionnaires as utilised in the ZQOL study
(e.g. ZBPI and SF-36) may be of value to doctors in
clinical practice, both in terms of obtaining symptom
and HRQoL reports directly from the patient themselves
and also providing patients with a perceived degree of
input into their own treatment decisions.
ZQOL study limitations and opportunities for further
research
The UK is a multi-cultural society, with findings from
the 2011 UK census indicating that 7.7million (14.0%) of
the population in England and Wales belonged to non-
white ethnic groups. However, it should be noted that
despite recruitment of HZ patients from regional sites
throughout the UK, the proportion of non-Caucasian
patients in the ZQOL study (0.4%) is lower than UK
population estimates and less than reported in prior
studies in this area [6,8,10]. That non-English speaking
HZ patients were excluded from participation in the
study may have contributed to the small number of non-
Caucasian patients, but this may also be reflective of obser-
vations that HZ is less common among non-Caucasian
populations [2]. Nonetheless, as a multi-cultural society,
follow-up work may be conducted to explore the burden
of HZ as it relates to ethnic minority patients in the UK.
Whilst cross-sectional data generated from the ZQOL
study and other studies provides insight into the collect-
ive burden experienced by patients with HZ, the lack of
long-term follow-up and repeated data collection over
time mean that there is limited understanding of the im-
pact of long-term complications of HZ. In particular,
research to help further understand factors that may ex-
plain the development of PHN in only a subset of HZ
patients (and identify those most at risk of developing
PHN) and to also understand the impact, at an individ-
ual level, that the progression of HZ to PHN has on pa-
tients (particularly in terms of pain and HRQoL impact)
would be of value.
Research evaluating the burden of the HZ and PHN
has, to date, focussed almost exclusively on patient-
centred outcomes and costs incurred by healthcare sys-
tems and society. However, as a disease most prevalent
among those aged 50 years or over, many of whom
(based on ZQOL study data) are expected to be living
with someone else, it is likely that a significant propor-
tion of patients will receive regular assistance from infor-
mal caregivers. The impact on these caregivers providing
care to a patient both during the acute presentation and
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HZ and during any long-term complications (e.g. PHN),
however, remains largely unexplored.
Finally, while information collected using formal PRO
questionnaires provides a valid means of ‘quantifying’
the burden of HZ, qualitative research exploring the ‘lived
experience’ of HZ from a patient’s perspective would be
beneficial for further understanding the burden and unmet
needs among HZ patients. To the authors’ knowledge,
however, no qualitative accounts of the experiences of HZ
and PHN within the scientific literature have been pub-
lished to date.
Conclusions
As the largest and first UK-wide cross-sectional study
conducted in HZ patients, the ZQOL study provides
much needed information regarding the characterisation
and management of HZ and the resulting burden associ-
ated with the condition from a patient and wider societal
perspective. The data from this study offer further sup-
port to the characterisation of HZ as a painful condition
that can have a significant impact on patients’ lives and
result in significant costs for healthcare providers. Data
from this study also highlight the current unmet need
and inadequacy of current treatments in HZ patients, re-
inforcing the need for effective preventative strategies
(such as vaccination) and early intervention.
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